Diversity of killer cell immunoglobulin-like receptor genes in uveitis associated with autoimmune diseases: Ankylosing spondylitis and behçet disease

Ocular Immunology and Inflammation

Volumn 21, Issue 2, 2013, Pages 135-143

  Moon, Su Jin ^a   Oh, Eun Jee ^b   Kim, Yonggoo ^b   Kim, Kyu Seop ^c   Kwok, Seung Ki ^a   Ju, Ji Hyeon ^a   Park, Kyung Su ^a   Kim, Ho Youn ^a   Park, Sung Hwan ^a  

^a The Catholic University of Korea   (South Korea)

^b Department of Laboratory Medicine ^*  (South Korea)

^c The Catholic University of Korea   (South Korea)

Author keywords

Ankylosing spondylitis; Beh et disease; KIR; KIR genotype; Uveitis

Indexed keywords

KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL1; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL2; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL3; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL4; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL5; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 3DL1; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 3DL2; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 3DL3; UNCLASSIFIED DRUG;

ANKYLOSING SPONDYLITIS; ARTICLE; BEHCET DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; KOREA; MAJOR CLINICAL STUDY; MALE; UVEITIS;

ADULT; ALLELES; BEHCET SYNDROME; DNA; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HLA-B27 ANTIGEN; HUMANS; MALE; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; RECEPTORS, KIR; SPONDYLITIS, ANKYLOSING; UVEITIS;

EID: 84876004923     PISSN: 09273948     EISSN: 17445078     Source Type: Journal    
DOI: 10.3109/09273948.2012.754905     Document Type: Article

References (53)

1. Brown MA, Laval SH, Brophy S, Calin A. Recurrence risk modelling of the genetic susceptibility to ankylosing spondylitis. Ann Rheum Dis. 2000;59:883-886
2. Brown MA, Kennedy LG, MacGregor AJ, et al. Susceptibility to ankylosing spondylitis in twins: The role of genes, HLA, and the environment. Arthritis Rheum. 1997;40:1823-1828
3. Verity DH, Wallace GR, Vaughan RW, Stanford MR. Behcet's disease: From Hippocrates to the third millennium. Br J Ophthalmol. 2003;87:1175-1183
4. Mizuki N, Ota M, Katsuyama Y, et al. Association analysis between the MIC-A and HLA-B alleles in Japanese patients with Behcet's disease. Arthritis Rheum. 1999;42:1961-1966
5. Ahmad T, Wallace GR, James T, et al. Mapping the HLA association in Behcet's disease: A role for tumor necrosis factor polymorphisms? Arthritis Rheum. 2003;48:807-813
6. Direskeneli H, Saruhan-Direskeneli G. The role of heat shock proteins in Behcet's disease. Clin Exp Rheumatol. 2003;21:S44-S48
7. Hatemi G, Bahar H, Uysal S, et al. The pustular skin lesions in Behcet's syndrome are not sterile. Ann Rheum Dis. 2004;63:1450-1452
8. Calguneri M, Ertenli I, Kiraz S, et al. Effect of prophylactic benzathine penicillin on mucocutaneous symptoms of Behcet's disease. Dermatology. 1996;192:125-128
9. Kaklamani VG, Vaiopoulos G, Kaklamanis PG. Behcet's disease. Semin Arthritis Rheum. 1998;27:197-217
10. Lehner T. The role of heat shock protein, microbial and autoimmune agents in the aetiology of Behcet's disease. Int Rev Immunol. 1997;14:21-32
11. Kibaroglu A, Eksioglu-Demiralp E, Akoglu T, Direskeneli H. T and NK cell subset changes with microbial extracts and human HSP60-derived peptides in Behcet's disease. Clin Exp Rheumatol. 2004;22:S59-S63
12. Scrivo R, Morrone S, Spadaro A, et al. Evaluation of degranulation and cytokine production in natural killer cells from spondyloarthritis patients at single-cell level. Cytometry B Clin Cytom. 2011;80:22-27
13. Kaneko F, Takahashi Y, Muramatsu Y, Miura Y. Immunological studies on aphthous ulcer and erythema nodosum-like eruptions in Behcet's disease. Br J Dermatol. 1985;113:303-312
14. Kaneko F, Takahashi Y, Muramatsu R, et al. Natural killer cell numbers and function in peripheral lymphoid cells in Behcet's disease. Br J Dermatol. 1985;113:313-318
15. Jiao YL, Ma CY, Wang LC, et al. Polymorphisms of KIRs gene and HLA-C alleles in patients with ankylosing spondylitis: Possible association with susceptibility to the disease. J Clin Immunol. 2008;28:343-349
16. Hamzaoui K, Ayed K, Hamza M, Touraine JL. Natural killer cells in Behcet's disease. Clin Exp Immunol. 1988;71:126-131
17. Eksioglu-Demiralp E, Direskeneli H, Ergun T, et al. Increased CD4+CD16+and CD4+CD56+T cell subsets in Behcet's disease. Rheumatol Int. 1999;19:23-26
18. Lanier LL. NK cell receptors. Annu Rev Immunol. 1998; 16:359-393
19. Carrington M, Martin MP. The impact of variation at the KIR gene cluster on human disease. Curr Top Microbiol Immunol. 2006;298:225-257
20. Boyton RJ, Altmann DM. Natural killer cells, killer immunoglobulin-like receptors and human leucocyte antigen class I in disease. Clin Exp Immunol. 2007;149:1-8
21. Suzuki Kurokawa M, Suzuki N. Behcet's disease. Clin Exp Med. 2004;4:10-20
22. Criteria for diagnosis of Behcet's disease. International Study Group for Behcet's Disease. Lancet. 1990; 335:1078-1080
23. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27:361-368
24. Whang DH, Park H, Yoon JA, Park MH. Haplotype analysis of killer cell immunoglobulin-like receptor genes in 77 Korean families. Hum Immunol. 2005;66:146-154
25. Ashouri E, Farjadian S, Reed EF, et al. KIR gene content diversity in four Iranian populations. Immunogenetics. 2009;61:483-492
26. Chan AT, Kollnberger SD, Wedderburn LR, Bowness P. Expansion and enhanced survival of natural killer cells expressing the killer immunoglobulin-like receptor KIR3DL2 in spondylarthritis. Arthritis Rheum. 2005;52: 3586-3595
27. Diaz-Pena R, Vidal-Castineira JR, Alonso-Arias R, et al. Association of the KIR3DS1.*013 and KIR3DL1. 004 alleles with susceptibility to ankylosing spondylitis. Arthritis Rheum. 2010;62:1000-1006
28. Zvyagin IV, Mamedov IZ, Britanova OV, et al. Contribution of functional KIR3DL1 to ankylosing spondylitis. Cell Mol Immunol. 2010;7:471-476
29. Mousavi T, Poormoghim H, Moradi M, et al. Inhibitory killer cell immunoglobulin-like receptor KIR3DL1 in combination with HLA-B Bw4iso protect against ankylosing spondylitis. Iran J Immunol. 2010;7:88-95
30. El Maghraoui A. Extra-Articular manifestations of ankylosing spondylitis: Prevalence, characteristics and therapeutic implications. Eur J Intern Med. 2011;22:554-560
31. Levinson RD, Martin TM, Luo L, et al. Killer cell immunoglobulin-like receptors in HLA-B27-Associated acute anterior uveitis, with and without axial spondyloarthropathy. Invest Ophthalmol Vis Sci. 2010; 51:1505-1510
32. Middleton D, Meenagh A, Sleator C, et al. No association of KIR genes with Behcet's disease. Tissue Antigens. 2007;70:435-438
33. Saruhan-Direskeneli G, Uyar FA, Cefle A, et al. Expression of KIR and C-Type lectin receptors in Behcet's disease. Rheumatology (Oxford). 2004;43:423-427
34. Colonna M, Borsellino G, Falco M, et al. HLA-C is the inhibitory ligand that determines dominant resistance to lysis by NK1-And NK2-specific natural killer cells. Proc Natl Acad Sci U S A. 1993;90:12000-12004
35. Wagtmann N, Biassoni R, Cantoni C, et al. Molecular clones of the p58 NK cell receptor reveal immunoglobulinrelated molecules with diversity in both the extra-And intracellular domains. Immunity. 1995;2:439-449
36. Winter CC, Long EO. A single amino acid in the p58 killer cell inhibitory receptor controls the ability of natural killer cells to discriminate between the two groups of HLA-C allotypes. J Immunol. 1997;158:4026-4028
37. Martin MP, Gao X, Lee JH, et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet. 2002;31:429-434
38. Stewart CA, Laugier-Anfossi F, Vely F, et al. Recognition of peptide-MHC class I complexes by activating killer immunoglobulin-like receptors. Proc Natl Acad Sci U S A. 2005;102:13224-13229
39. Kulkarni S, Martin MP, Carrington M. The yin and yang of HLA and KIR in human disease. Semin Immunol. 2008; 20:343-352
40. Carr WH, Pando MJ, Parham P. KIR3DL1 polymorphisms that affect NK cell inhibition by HLA-Bw4 ligand. J Immunol. 2005;175:5222-5229
41. Khakoo SI, Geller R, Shin S, et al. The D0 domain of KIR3D acts as a major histocompatibility complex class I binding enhancer. J Exp Med. 2002;196:911-921
42. Evans DM, Spencer CC, Pointon JJ, et al. Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLAB27 in disease susceptibility. Nat Genet. 2011;43:761-767
43. Kollnberger S, Chan A, Sun MY, et al. Interaction of HLAB27 homodimers with KIR3DL1 and KIR3DL2, unlike HLA-B27 heterotrimers, is independent of the sequence of bound peptide. Eur J Immunol. 2007;37:1313-1322
44. Bowness P, Ridley A, Shaw J, et al. Th17 cells expressing KIR3DL2+and responsive to HLA-B27 homodimers are increased in ankylosing spondylitis. J Immunol. 2011; 186:2672-2680
45. Hirohata S, Kikuchi H. Behcet's disease. Arthritis Res Ther. 2003;5:139-146
46. Rajendram R, Rao NA. Molecular mechanisms in Behcet's disease. Br J Ophthalmol. 2003;87:1199-1200
47. Mizuki N, Ohno S, Sato T, et al. Microsatellite polymorphism between the tumor necrosis factor and HLA-B genes in Behcet's disease. Hum Immunol. 1995;43:129-135
48. Mizuki N, Ota M, Katsuyama Y, et al. HLA-B.*51 allele analysis by the PCR-SBT method and a strong association of HLA-B. 5101 with Japanese patients with Behcet's disease. Tissue Antigens. 2001;58:181-184
49. Levinson RD, Du Z, Luo L, et al. Combination of KIR and HLA gene variants augments the risk of developing birdshot chorioretinopathy in HLA-A.*29-positive individuals. Genes Immun. 2008;9:249-258
50. Yang KL, Chen IH, Hsiao CK, et al. Polymorphism of HLAB27 in Taiwanese Chinese. Tissue Antigens. 2004;63:476-479
51. Shahsavar F, Mousavi T, Azargon A, Entezami K. Association of KIR3DS1+HLA-B Bw4Ile80 combination with susceptibility to tuberculosis in Lur population of Iran. Iran J Immunol. 2012;9:39-47
52. Hirayasu K, Ohashi J, Kashiwase K, et al. Significant association of KIR2DL3-HLA-C1 combination with cerebral malaria and implications for co-evolution of KIR and HLA. PLoS Pathog. 2012;8:e1002565
53. Suppiah V, Gaudieri S, Armstrong NJ, et al. IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European cohort: A cross-sectional study. PLoS Med. 2011;8:e1001092